{"id":1689,"date":"2025-07-17T13:00:53","date_gmt":"2025-07-17T04:00:53","guid":{"rendered":"https:\/\/www.kr-geninus.com\/?p=1689"},"modified":"2025-07-18T09:05:07","modified_gmt":"2025-07-18T00:05:07","slug":"2025-07-15-biomarkers-for-successful-immune-checkpoint-adc-drug-development","status":"publish","type":"post","link":"https:\/\/www.kr-geninus.com\/?p=1689","title":{"rendered":"[2025\/07\/15] Biomarkers for Successful Immune Checkpoint &#038; ADC Drug Development"},"content":{"rendered":"<p>Utilizing Biomarkers for Successful Development of Immune Checkpoint Inhibitors and ADC New Drugs<br \/>\nGeninus Inc., Samsung Medical Center Translational Genomics Center, and Sungkyunkwan University School of Medicine \u2014 Woongyang Park<\/p>\n<p>Overview<\/p>\n<p>Healthcare is rapidly transitioning into the era of precision medicine, which focuses on patient-specific tailored treatments. Particularly in anticancer drug development, treatment strategies based on the molecular and cellular characteristics of tumors are becoming increasingly important. Biomarkers are indicators that can predict disease traits or drug responses, including various forms such as gene mutations, gene\/protein expression, and circulating tumor DNA. Utilizing these biomarkers enables the prediction of patient treatment responses in advance and monitoring of treatment progress, making them essential tools in new drug development and anticancer drug selection. In fact, new drug development strategies incorporating biomarkers have been associated with expanded responder populations, prolonged progression-free survival (PFS), improved overall survival (OS), and are reported to increase the success rate and shorten the development timeline. Conversely, development without biomarkers targeting broad patient populations carries a higher risk of failure. This paper introduces the necessity and current trends of biomarkers to promote globally competitive domestic new drug development. \u00a0\u00a0<a href=\"https:\/\/www.kr-geninus.com\/wp-content\/uploads\/2025\/07\/Biomarker-Use-for-Successful-Immune-Checkpoint-and-ADC-Drug-Development-\u2014-Woongyang-Park-Geninus-CEO.pdf\" download=\"\">Download(English Ver)-&gt;<\/a><\/p>\n<p>\u25a0Source:: <a href=\"https:\/\/www.kddf.org\/ko\/board\/research\/view\/?bc_no=2643&amp;page=1\">KDDF<\/a><\/p>\n<p>\uc131\uacf5\uc801\uc778 \uba74\uc5ed\ud56d\uc554\uc81c \ubc0f ADC \uc2e0\uc57d\uac1c\ubc1c\uc744 \uc704\ud55c \ubc14\uc774\uc624\ub9c8\ucee4 \ud65c\uc6a9<br \/>\n\u321c\uc9c0\ub2c8\ub108\uc2a4, \uc0bc\uc131\uc11c\uc6b8\ubcd1\uc6d0 \uc911\uac1c\uc720\uc804\uccb4\uc13c\ud130 \ubc0f \uc131\uade0\uad00\ub300\ud559\uad50 \uc758\uacfc\ub300\ud559 \ubc15\uc6c5\uc591<\/p>\n<p>Overview<\/p>\n<p>\uc774\uc81c \uc758\ub8cc\ub294 \ud658\uc790\ubcc4 \ub9de\ucda4 \uce58\ub8cc\uc778 \uc815\ubc00\uc758\ub8cc(precision medicine) \uc2dc\ub300\ub85c \uae09\uc18d\ud788 \uc804\ud658\ub418\uace0 \uc788\ub2e4. \ud2b9\ud788 \ud56d\uc554\uc81c \uac1c\ubc1c\uc5d0\uc11c \uc885\uc591\uc758 \ubd84\uc790 \ubc0f \uc138\ud3ec\uc758 \ud2b9\uc131\uc5d0 \uae30\ubc18\ud55c \uce58\ub8cc\uc804\ub7b5\uc774 \uc911\uc694\ud574\uc9c0\uace0 \uc788\ub2e4. \ubc14\uc774\uc624\ub9c8\ucee4(biomarker)\ub780 \uc9c8\ubcd1\uc758 \ud2b9\uc131\uc774\ub098 \uc57d\ubb3c \ubc18\uc751\uc744 \uc608\uce21\ud560 \uc218 \uc788\ub294 \uc9c0\ud45c\ub85c\uc11c, \uc720\uc804\uc790 \ub3cc\uc5f0\ubcc0\uc774, \uc720\uc804\uc790\/\ub2e8\ubc31\uc9c8 \ubc1c\ud604, \uc21c\ud658 \uc885\uc591 DNA \ub4f1 \ub2e4\uc591\ud55c \ud615\ud0dc\uac00 \uc788\ub2e4. \uc774\ub7ec\ud55c \ubc14\uc774\uc624\ub9c8\ucee4\ub97c \ud65c\uc6a9\ud558\uba74 \ud658\uc790\uc758 \uce58\ub8cc \ubc18\uc751\uc744 \uc0ac\uc804\uc5d0 \uc608\uce21\ud558\uac70\ub098 \uce58\ub8cc \uacbd\uacfc\ub97c \ubaa8\ub2c8\ud130\ub9c1\ud560 \uc218 \uc788\uc5b4, \uc2e0\uc57d\uac1c\ubc1c\uacfc \ud56d\uc554\uc81c \uc120\uc815\uc5d0 \ud544\uc218\uc801\uc778 \ub3c4\uad6c\uac00 \ub418\uace0 \uc788\ub2e4. \uc2e4\uc81c\ub85c \ubc14\uc774\uc624\ub9c8\ucee4\ub97c \ud1b5\ud569\ud55c \uc2e0\uc57d\uac1c\ubc1c \uc804\ub7b5\uc740 \uce58\ub8cc\ubc18\uc751\uad70 \ud655\ub300, \ubb34\uc9c4\ud589\uc0dd\uc874\uae30\uac04(PFS) \uc5f0\uc7a5 \ubc0f \uc804\uccb4\uc0dd\uc874(OS) \uac1c\uc120\uacfc \uc5f0\uad00\ub418\uba70, \uac1c\ubc1c \ud504\ub85c\uadf8\ub7a8\uc758 \uc131\uacf5 \ud655\ub960\uc744 \ub192\uc774\uace0 \uac1c\ubc1c \uae30\uac04\uc744 \ub2e8\ucd95\ud558\ub294 \uac83\uc73c\ub85c \ubcf4\uace0\ub418\uace0 \uc788\ub2e4. \ubc18\ub300\ub85c \ubc14\uc774\uc624\ub9c8\ucee4 \uc5c6\uc774 \uad11\ubc94\uc704\ud55c \ud658\uc790\uad70\uc744 \ub300\uc0c1\uc73c\ub85c \ud55c \uac1c\ubc1c\uc740 \uc2e4\ud328 \uc704\ud5d8\uc774 \ud070 \uac83\uc73c\ub85c \ud3c9\uac00\ub41c\ub2e4. \uc774\uc5d0 \uae00\ub85c\ubc8c \uacbd\uc7c1\ub825\uc744 \uac16\ucd98 \uad6d\ub0b4\uc2e0\uc57d \uac1c\ubc1c\uc744 \uc704\ud574 \ubc14\uc774\uc624\ub9c8\ucee4 \uce21\uba74\uc5d0\uc11c \uadf8 \ud544\uc694\uc131\uacfc \ub3d9\ud5a5 \ub4f1\uc744 \uc18c\uac1c\ud558\uace0\uc790 \ud55c\ub2e4. \u00a0<a href=\"https:\/\/www.kr-geninus.com\/wp-content\/uploads\/2025\/07\/\uc131\uacf5\uc801\uc778-\uba74\uc5ed\ud56d\uc554\uc81c-\ubc0f-ADC-\uc2e0\uc57d\uac1c\ubc1c\uc744-\uc704\ud55c-\ubc14\uc774\uc624\ub9c8\ucee4-\ud65c\uc6a9_\uc9c0\ub2c8\ub108\uc2a4-\ubc15\uc6c5\uc591-\ub300\ud45c.pdf\" download=\"\">\ub2e4\uc6b4\ub85c\ub4dc(\ud55c\uad6d\uc5b4)-&gt;<\/a><\/p>\n<p>\u25a0\ucd9c\ucc98: <a href=\"https:\/\/www.kddf.org\/ko\/board\/research\/view\/?bc_no=2643&amp;page=1\">KDDF<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Utilizing Biomarkers for Successful Development of Immune Checkpoint Inhibitors and ADC New Drugs Geninus Inc., Samsung Medical Center Translational Genomics Center, and Sungkyunkwan University School of Medicine \u2014 Woongyang Park Overview Healthcare is rapidly transitioning into the era of precision medicine, which focuses on patient-specific tailored treatments. Particularly in anticancer drug development, treatment strategies based [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[37],"tags":[],"class_list":["post-1689","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=\/wp\/v2\/posts\/1689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1689"}],"version-history":[{"count":5,"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=\/wp\/v2\/posts\/1689\/revisions"}],"predecessor-version":[{"id":1697,"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=\/wp\/v2\/posts\/1689\/revisions\/1697"}],"wp:attachment":[{"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.kr-geninus.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}